Breadcrumb

AIDSFree Prevention Update: January 2016

In Focus this month:

AIDS By The Numbers 2015
(Joint United Nations Programme on HIV/AIDS)
This report acknowledges dramatic declines in new HIV infections and AIDS-related deaths over time, but emphasizes that accelerating the AIDS response in low- and middle-income countries could avert 28 million new HIV infections and 21 million AIDS-related deaths between 2015 and 2030, saving US$24 billion annually in additional HIV treatment costs. 

Pre-exposure Prophylaxis (PrEP) Reduces Men's HIV-1 Risk
(New England Journal of Medicine)
This double-blind, randomized trial of PrEP use showed that the use of a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) before and after unprotected anal sex between men reduced the risk of HIV-1 infection by 86 percent.

Antiretroviral Therapy Scale-up: What Gaps Remain?
(PLOS ONE)
This modeling study projected service use and facility-level costs for the scale-up of antiretroviral therapy (ART) in 97 countries from 2015 to 2020. Analysis of several scenarios predicted a six-year financing gap ranging from US$19.8 billion to $25.0 billion. This shortfall could significantly hamper countries' ability to meet the "90-90-90" ART targets proposed by the Joint United Nations Programme on HIV/AIDS. 

Expand Community-based HIV Testing to Reduce Service Gaps
(Nature)
This meta-analysis compared facility- and community-based HIV testing approaches and found that community-based testing achieved higher coverage overall. Expanding home and mobile testing and outreach to key populations with facilitated linkage can decrease the HIV burden and increase the proportion of men, young adults, and key populations connected to HIV treatment and prevention. 

Is an HIV Vaccine Necessary?
(New England Journal of Medicine)
This article urged the HIV community to continue scaling up the delivery of antiretroviral therapy and prevention, but also to remain committed to vaccine science. A sustainable end to the HIV pandemic lies in a combination of non-vaccine prevention methods and deployment of a safe, effective HIV vaccine.